EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of Cancer

Rebecca A Gallego iD, Sujin Cho-Schultz, Matthew Del Bel, Anne-Marie Dechert-Schmitt, Joyann S Donaldson iD, Mingying He, Mehran Jalaie, Rob Kania, Jean Matthews, Michele McTigue, Jamison B Tuttle, Hud Risley und 38 weitere

Journal of Medicinal Chemistry · 26.12.2024 · 67 (24) · 22002-22038

DOI: 10.1021/acs.jmedchem.4c01930 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 09.12.2024. Verfasst von Rebecca A Gallego und 49 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Medicinal Chemistry Worldwide Research and Development, Pfizer, Inc., 10770 Science Center Drive, La Jolla, California 92121, United States. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Protein Serine-Threonine Kinases, Drug Discovery. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 59 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hematopoietic progenitor kinase 1 (HPK1/MAP4K1) represents a high interest target for the treatment of cancer through an immune-mediated mechanism. Herein we present highlights of the drug discovery campaign within the lactam/azalactam series of inhibitors that yielded a small molecule (21, PF-07265028), which was advanced to a phase 1 clinical trial (NCT05233436). Key components of the discovery effort included optimization of potency through mitigation of ligand strain as guided by the use of cocrystal structures, mitigation of ADME liabilities (plasma instability and fraction metabolism by CYP2D6), and optimization of kinase selectivity, particularly over immune-modulating kinases with high homology to HPK1. Structure-based drug design via leveraging cocrystal structures and lipophilic efficiency analysis proved to be valuable tools that ultimately enabled the delivery of a clinical-quality small molecule inhibitor of HPK1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsProtein Serine-Threonine KinasesDrug DiscoveryHumansStructure-Activity RelationshipAnimalsAntineoplastic AgentsSmall Molecule LibrariesNeoplasmsMolecular Structure

Substanzen

Protein Kinase Inhibitorshematopoietic progenitor kinase 1Protein Serine-Threonine KinasesAntineoplastic AgentsSmall Molecule Libraries

Autor:innen und Institutionen

  • Oncology Medicinal Chemistry Worldwide Research and Development, Pfizer, Inc., 10770 Science Center Drive, La Jolla, California 92121, United States.
  • Worldwide Research and Development, Pfizer, Inc., Groton, Connecticut 06340, United States.
  • Worldwide Research and Development, Pfizer, Inc., Cambridge, Massachusetts 02139, United States.
  • Pharmacokinetics, Dynamics and Metabolism Worldwide Research and Development, Pfizer, Inc., 10770 Science Center Drive, La Jolla, California 92121, United States.
  • Oncology Research Unit Worldwide Research and Development, Pfizer, Inc., 10770 Science Center Drive, La Jolla, California 92121, United States.

ORCID-Profile: Rebecca A Gallego, Joyann S Donaldson, Omar K Ahmad, Simon Berritt, John Braganza, Scott P France, Thomas Knauber, Paul Richardson, Lei Zhang, Sajiv K Nair

Zitieren

APA

Gallego, R. A., Cho-Schultz, S., Del Bel, M., Dechert-Schmitt, A. M., Donaldson, J. S., He, M., Jalaie, M., Kania, R., Matthews, J., McTigue, M., Tuttle, J. B., Risley, H., Zhou, D., Zhou, R., Ahmad, O. K., Bernier, L., Berritt, S., Braganza, J., Chen, Z., …, & Nair, S. K. (2024). Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of Cancer. Journal of Medicinal Chemistry, 67(24), 22002-22038. https://doi.org/10.1021/acs.jmedchem.4c01930

Vancouver

Gallego RA, Cho-Schultz S, Del Bel M, Dechert-Schmitt AM, Donaldson JS, He M, et al. Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of Cancer. Journal of Medicinal Chemistry. 2024;67(24):22002-22038. doi:10.1021/acs.jmedchem.4c01930

BibTeX
@article{Gallego2024,
  author = {Gallego, Rebecca A and Cho-Schultz, Sujin and Del Bel, Matthew and Dechert-Schmitt, Anne-Marie and Donaldson, Joyann S and He, Mingying and Jalaie, Mehran and Kania, Rob and Matthews, Jean and McTigue, Michele and Tuttle, Jamison B and Risley, Hud and Zhou, Dahui and Zhou, Ru and Ahmad, Omar K and Bernier, Louise and Berritt, Simon and Braganza, John and Chen, Zecheng and Cianfrogna, Julie A and Collins, Michael and Costa Jones, Cinthia and Cronin, Ciaran N and Davis, Carl and Dress, Klaus and Edwards, Martin and Farrell, William and France, Scott P and Grable, Nicole and Johnson, Eric and Johnson, Ted W and Jones, Rhys and Knauber, Thomas and Lafontaine, Jennifer and Loach, Richard P and Maestre, Michael and Miller, Nichol and Moen, Mark and Monfette, Sebastien and Morse, Peter and Nager, Andrew Ross and Niosi, Mark and Richardson, Paul and Rohner, Allison K and Sach, Neal W and Timofeevski, Sergei and Tucker, Joseph W and Vetelino, Beth and Zhang, Lei and Nair, Sajiv K},
  title = {Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {24},
  pages = {22002--22038},
  doi = {10.1021/acs.jmedchem.4c01930}
}
Kostenlos starten →